Lay Title: Stool Microbiome Study
Technical Title: Stool Microbiome and Immunotherapy Response and Toxicity
Disease Type: Patients with recently diagnosed metastatic kidney cancer (mRCC) or metastatic urothelial carcinoma (mUC) and new prescription for immunotherapy.
Cancer immunotherapy is now used in many cancers including drugs which block a specific pathway (PD-1). Exciting data has linked the response to immune therapy with the type of stool bacteria that live in the gut. We now have the potential to study the bacteria which live in one’s gut by testing the stool. We still do not know which stool bacteria are associated with better response, but if this is discovered in the future, there is the potential to alter the bacteria in order to improve outcome with these cancer therapies. We are performing this study in order to better understand which bacteria are present in our patients and if it changes with therapy. We hope to obtain more information on which bacteria (if any) are associated with an improved outcome and less toxicity to inform future work in this area.
Research Procedures (not a complete list):
Subjects will provide stool samples for testing at various time points. A first stool sample before receiving treatment, a second stool sample before receiving follow-up imaging after treatment, and additional stool samples if disease status changes in the future.
Eligibility Criteria (Not a complete list):
For More Detailed Information, Contact: